Company: ZZ Biotech
Drug Type: Protein Biologic
Conditions: ALS, stroke, sepsis
Mechanism Type: Neuroprotection
Mechanism: 3K3A-APC is a recombinant Activated Protein C (APC), a protease with anticoagulant and cytoprotective properties for the aging and damaged brain. The CNS-penetrant drug candidate is being developed for stroke and other neurodegenerative disorders. Preclinical studies in SOD1 ALS mouse models have shown that 3K3-APC treatment increases lifespan by 13% and disease duration by 28% compared to saline treated control. The drug is no longer being actively developed for ALS.
U.S. Status for ALS: Inactive
 ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC B3C Newswire, 29 Jan 2018. Accessed 8 Feb 2018 from http://www.b3cnewswire.com/201801291715/zz-biotech-announces-preliminary-phase-2-stroke-trial-results-with-3k3a-apc.html
 ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures. B3C Newswire, 22 Apr 2014. Accessed 11 Mar 2016 from http://www.b3cnewswire.com/201404221062/zz-biotech-announces-phase-2-trial-with-3k3a-apc-in-stroke-funds-will-be-provided-by-nih-and-broadview-ventures.html.
 Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Winkler, EA et al. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):E1035-42.
 Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. Zhong, Z et al. J Clin Invest. 2009 Nov 2; 119(11): 3437–3449.
Last updated February 13th, 2018